ZIVO vs. CRDF, OMGA, ELUT, HLVX, ALVR, BCAB, SGMO, TIL, GNTA, and DBVT
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Cardiff Oncology (CRDF), Omega Therapeutics (OMGA), Elutia (ELUT), HilleVax (HLVX), AlloVir (ALVR), BioAtla (BCAB), Sangamo Therapeutics (SGMO), Instil Bio (TIL), Genenta Science (GNTA), and DBV Technologies (DBVT). These companies are all part of the "biological products, except diagnostic" industry.
ZIVO Bioscience (NASDAQ:ZIVO) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
In the previous week, Cardiff Oncology had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Cardiff Oncology and 0 mentions for ZIVO Bioscience. Cardiff Oncology's average media sentiment score of 0.54 beat ZIVO Bioscience's score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media.
Cardiff Oncology has a consensus price target of $10.50, indicating a potential upside of 348.72%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than ZIVO Bioscience.
ZIVO Bioscience has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.
12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by insiders. Comparatively, 7.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cardiff Oncology has a net margin of -6,594.92% compared to ZIVO Bioscience's net margin of -11,068.75%. ZIVO Bioscience's return on equity of 0.00% beat Cardiff Oncology's return on equity.
ZIVO Bioscience has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500.
ZIVO Bioscience received 61 more outperform votes than Cardiff Oncology when rated by MarketBeat users. However, 62.30% of users gave Cardiff Oncology an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.
Summary
Cardiff Oncology beats ZIVO Bioscience on 12 of the 18 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
